Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Hypermobility spectrum disorder and Ehlers-Danlos syndromes

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Possible vascular or organ rupture

Sudden severe chest, abdominal, flank, head or limb pain, collapse, focal neurology, haemoptysis or major unexplained bleeding in suspected vascular EDS can indicate arterial dissection, rupture, pneumothorax or bowel perforation.

Action: Call emergency vascular-capable services, state the possible connective-tissue disorder, minimise traumatic procedures, obtain rapid specialist-led imaging and involve vascular surgery, interventional radiology, anaesthesia and genetics-informed teams.

Synopsis

Assess symptomatic joint hypermobility systematically, distinguish hypermobile Ehlers-Danlos syndrome from hypermobility spectrum disorder and monogenic EDS subtypes, recognise vascular danger, and coordinate stabilising rehabilitation, symptom care, genetics and reproductive planning.

  • Joint hypermobility is a physical trait; HSD or hEDS requires symptoms or associated features after exclusion of another explanation, and neither follows from flexibility alone.
  • Score Beighton manoeuvres correctly: the 2017 hEDS threshold is at least 5 of 9 from puberty through age 50 and at least 4 after 50; historical questions help when one point below.
  • All hEDS groups are required: generalised hypermobility; at least two of Feature A with five systemic findings, Feature B with an independently affected first-degree relative, or Feature C with qualifying pain or instability; and complete exclusions.
  • There is no confirmatory genetic test for hEDS; molecular testing is directed by features of vascular, classical or another monogenic subtype, not ordered as a generic hypermobility panel.
  • HSD can be as functionally important as hEDS; management is based on instability, pain, fatigue and comorbidity rather than perceived label rank.
  • Use progressive proprioceptive, strength and movement-control rehabilitation, pacing, task adaptation and selected braces; aggressive stretching or prolonged immobilisation can worsen stability and deconditioning.
  • Sudden severe chest, abdominal, head or limb pain in suspected vascular EDS is an emergency; state the diagnosis because imaging, access and operative strategy require tissue-fragility expertise.
  • Pregnancy planning should identify subtype where possible; vascular EDS needs genetics and maternal medicine, while hEDS or HSD benefits from pelvic-health and anaesthetic planning.

Key red flags

Arterial rupture or dissection, spontaneous bowel perforation, uterine rupture, pneumothorax or unexplained sudden death in a young first-degree relative raises vascular EDS and warrants specialist genetics assessment.

Marked skin fragility with broad atrophic scars, easy tearing, congenital hip dislocation, severe progressive scoliosis, ocular rupture or early periodontal loss suggests a monogenic subtype.

A hot swollen joint after a procedure or injury, fever, severe unremitting bone pain or progressive neurological loss requires an infection, fracture or compression pathway.

Syncope during exertion, chest pain, sustained tachyarrhythmia or focal neurological events must not be assumed to be benign dysautonomia without acute assessment.

Investigation priorities

01
First-line structured assessmentFirst stepFirst line

Confirm current and historical hypermobility, document functional consequences and detect signs requiring another route.

Management branches

First-line classificationSeparate trait, HSD, hEDS and rare subtype

Recurrent pain, instability or systemic connective-tissue features accompany current or historical hypermobility.

  1. Measure Beighton score correctly, document non-Beighton and historical mobility, and establish whether symptoms are plausibly related rather than incidental.
  2. Apply all hEDS criteria groups, examining systemic features and excluding inflammatory, neuromuscular, skeletal and alternative heritable disorders.
  3. Diagnose HSD when symptomatic hypermobility remains important but hEDS and another defined disorder are not met, explaining that treatment need is not label-dependent.
  4. Refer to clinical genetics when vascular, classical, ocular, skeletal or other distinctive fragility makes a molecular subtype plausible.
Preferred rehabilitationBuild active joint control

Instability, pain, fatigue or movement fear limits function without fracture, unreduced dislocation or emergency.

  1. Begin proprioception, neutral-position awareness, low-load closed-chain strength and movement quality, progressing repetitions, resistance and complexity gradually.
  2. Use pacing and aerobic conditioning to reduce boom-and-bust activity while avoiding repeated end-range demonstrations and aggressive stretching.
  3. Add occupational adaptation, footwear, tape or task-specific brace when it improves function, and maintain active muscle support rather than permanent immobilisation.

Key medicines

Paracetamol for acute local painUse 500 mg–1 g orally at intervals of at least four hours when required, maximum 4 g in 24 hours for a suitable adult; lower the ceiling with low weight, frailty or liver risk.Avoid duplicated combination products and chronic automatic use without benefit; adjust for liver disease and alcohol. It does not stabilise collagen or prevent dislocation.
Topical diclofenac gelApply a product-specific amount to focal pain, commonly 2–4 g of 1.16% gel three or four times daily for a brief trial, without exceeding the product maximum.Avoid fragile damaged skin, NSAID hypersensitivity and excess combined NSAIDs; systemic harms remain possible. In pregnancy use only when clearly necessary and avoid during the third trimester.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS Ehlers-Danlos syndromesUK symptom, subtype, inheritance and referral overview.
  • 2017 hypermobile EDS diagnostic checklistAdult Beighton thresholds and full clinical criteria.
  • GeneReviews Hypermobile Ehlers-Danlos syndromeClinical diagnosis, management and pregnancy.
  • GeneReviews Vascular Ehlers-Danlos syndromeCOL3A1 diagnosis, emergencies and reproductive risk.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Treat each acute sprain, tendon lesion, nociplastic component and sleep or mood disorder according to its own mechanism.